Organic Active Ingredients TRIZ Cases

Threonine, valine, tyrosine, tryptophan, and serine compositions protect intestinal stem cells from radiation damage and enhance cellular survival.

Hybrid arylcyclohexylether dihydrotetraazabenzoazulene molecules resolve the contradiction between blood-brain barrier penetration and V2 receptor selectivity.

Enzymatic hydrolysis removes sugars from ginseng saponin, overcoming low absorption rates caused by high sugar content.

A stable Abiraterone acetate complex enhances solubility and dissolution rate through specific excipient interactions.

An ApoCIII-specific antisense compound reduces triglycerides and increases HDL levels in patients with lipoprotein lipase deficiency.

TLR agonist compositions reduce RNA dose and side effects by modulating interferon suppression.

Size exclusion chromatography isolates ethyl maltol from passionflower extracts, resolving detection limits of conventional methods.

Dispersing acid-insoluble polymers in Type A gelatin prevents orange peel defects while maintaining gastric protection.

CGP3466B blocks GAPDH nitrosylation to resolve the contradiction between effective treatment reliability and molecular pathway complexity.

Ibudilast reverses chemical-induced lung injury by reducing inflammation, addressing the gap where standard neurodegenerative treatments fail.

Substituted pyrazolopyrimidine compounds inhibit PDE1B enzyme activity to modulate intracellular signaling pathways.

ZL-n-91 selectively inhibits PDE4D to suppress prostate cancer cell proliferation, avoiding gastrointestinal side effects from non-specific enzyme inhibition.

Partial CLEC16A reduction achieves significant weight loss without exacerbating autoimmune phenotypes.

GZ440-6 fused bicyclic compound reduces viral loads and RNA levels while maintaining low cytotoxicity against host cells.

Combining a 2-iminopyrrolidine derivative with aspirin or clopidogrel overcomes insufficient single-agent effectiveness in treating heart diseases.

Thermoresponsive liquogels enable localized drug release at target tissues, reducing systemic side effects from invasive procedures.

A polysaccharide mixture containing beta-glucans suppresses beta cell apoptosis to treat hyperglycemia.

Formulated as emulsions or nanosuspensions, these compositions treat pancreatitis and autoimmune diseases by regulating calcium influx.

Monophosphoryl lipid A activates Toll-like receptor 4 to reduce AMPA/NMDA ratios in D1-type medium spiny neurons.

Elastic alloy cage emits voltage field to enhance drug permeation, avoiding mechanical overexpansion that causes vessel diameter loss.

Combining RAD51 and PARP inhibitors creates a dual-target therapy regimen that blocks homologous recombination and base excision repair pathways.

Biosurfactants suppress inflammatory responses and inhibit oxidative stress to delay neurodegenerative symptom onset.

Segmenting the core scaffold into diverse series overcomes drug resistance in existing CK2 inhibitors while maintaining potent cytotoxic activity.

Segmented genomic polynucleotides enable precise targeting of aberrant chromosome 12q13-q15 genes to treat sarcomas and leukemias.

Tetracyclic steroidal compounds modulate androgen receptor activity through specific C9 and C13 quaternary centers.

Bicyclic compounds block the YAP/TAZ-TEAD protein-protein interaction, disrupting oncogenic activity and addressing cancer metastasis challenges.

Intratumoral PLGA microparticles deliver doxorubicin and CpG to induce immunogenic cell death, breaking immune tolerance while reducing systemic toxicity.

Substituted oxazole derivatives act as potent inhibitors of Flt-3 and Syk kinases to modulate signal transduction pathways.

Tricyclo-DNA lipid oligonucleotides improve dystrophin rescue in Duchenne muscular dystrophy while reducing cardiac toxicity.

A glutamine-based pharmaceutical composition restores memory and cognitive ability while suppressing nerve cell damage in brain tissues.

Zwitterionic chitosan derivatives reduce immune activation while enabling pH-responsive dendrimer delivery.

Recombinant EGFL7 peptide induces T cell exhaustion and tolerance to treat graft-versus-host disease.

Synthesizing 3-pyrimidinyl pyrrolo[2,3-b]pyridine via palladium catalysis reduces clinical attrition for CDK inhibitors.

Oral neuroactive steroids gain bioavailability when taken with food, overcoming poor absorption and first-pass metabolism.

N-(pyridin-2-ylsulfonyl)cyclopropanecarboxamide derivatives restore CFTR protein function.

Merges abemaciclib with copanlisib to overcome venetoclax resistance and reduce chemotherapy side effects in aggressive mantle cell lymphoma.

Selective COX-2 inhibitors reduce gastrointestinal ulcers by sparing COX-1 enzymes that protect gastric mucosa integrity.

Genetic profiling of tumor mutational burden and cytolytic activity genes guides PVSRIPO treatment selection.

Segmenting the dosage into immediate and sustained phases reduces peak-to-valley fluctuations while maintaining therapeutic levels for 24 hours.

Vilazodone solid dispersion converts crystalline drug to amorphous state using water-soluble polymer carriers, improving solubility under fasting conditions.

Click chemistry joins azide platinum and alkyne oligomers, creating hybrids that crosslink purine-rich DNA sequences for targeted cancer therapy.

Benzo-fused heterocycle sulfamide derivatives stabilize mood while reducing side effects common with lithium carbonate.

Redox-sensitive DABCO-BBAC nanoparticles protect nucleic acids from degradation while targeting bacteria to minimize mammalian cell toxicity.

Pharmacological modulation of estrogen action reduces lower abdominal muscle fibrosis and atrophy, avoiding surgical morbidity in high-risk patients.

Modular pyrazolo-pyrimidine scaffolds achieve specific MALT1 inhibition, resolving uncontrolled immune responses and tumor development.

Sulfonylpyridine compounds extend half-life beyond native apelin limits, sustaining cardioprotective benefits.

Radiofrequency energy fuses surface stabilizing agents onto powder layers, resolving tablet fragility and chipping without complex processing steps.

Identifies specific gene loci to stratify patient risk profiles, resolving the trade-off between diagnostic precision and test complexity.

Stereochemically pure Rp,Rp cyclic purine dinucleotides overcome antigen tolerance by activating STING receptors in dendritic cells.

Esterified epinephrine prodrugs increase membrane permeability, enabling accurate non-invasive dosing without needle fear.

Fluoropolymer canister coatings and polyethylene glycol formulations enhance active ingredient delivery in pressurized metered dose inhalers.

An etonogestrel injectable formulation uses a triblock and diblock copolymer matrix to sustain drug release over 120 days.

Incorporating artificial powdered beef flavor into a non-chewable carprofen tablet resolves the trade-off between palatability and bioequivalence.

A clonidine liquid composition uses a phosphate buffer system to maintain chemical and physical stability.

Multi-phase silicone acrylic hybrid compositions use solvent exchange to control internal and external phase arrangement.

Ester bond hydrolysis releases HYA to resolve solid state and acrid flavor handling issues.

BGP-15 restores adiposity feedback signaling to reduce abnormal body weight gain despite leptin resistance.

Serum Fatty Acid Synthase measurement addresses the lack of validated biomarkers for diabetic foot wounds, enabling targeted cilostazol therapy.

4-bromo-N-imidazolidin-2-ylidene-1-H-benzimidazol-5-amine lowers intraocular pressure via alpha-2 adrenergic receptor activation.

Yeast cell wall particles trap nanoparticles inside their porous structure to enable controlled release and targeted cellular uptake.

Combining selinexor with an Akt inhibitor mitigates pro-oncogenic effects activated by the first agent, enhancing anti-cancer efficacy.

Non-deacetylated xanthan gum stabilizes corticosteroid suspensions, preventing viscosity drift and ensuring rapid redispersion after storage.

Targeted biopolymer formulation treats equine hepatic insufficiency without requiring rest or behavioral modifications.

Sequential high and low dose beta-glucan regimens boost anti-tumor immunity without causing liver or kidney deterioration.

Measuring stathmin levels in tumor samples predicts response to furazanobenzimidazoles like BAL27862.

Cyclodextrin mediates inclusion complexes that shield botulinum neurotoxin from denaturation, extending shelf life beyond four hours.

Inhibiting let-7 microRNAs and increasing Lin28 activity prolongs organogenesis, expanding functional nephrons without dexamethasone side effects.

A pyrimidine piperidine compound modulates glucose metabolism by acting as a selective RUP3 receptor agonist.

Combining TAM kinase and BCL-2 inhibitors reduces leukemia burden while lowering toxicity through synergistic potency.

Alginate carriers improve drug release and bioavailability while maintaining stability against heat, light, and humidity.

Anti-IκBα agents activate latent HIV reservoirs in resting memory CD4 T cells, countering viral latency barriers to eradication.

A nitrogen-containing heterocyclic compound inhibits bromodomain binding to acetylated histones.

An effervescent pramipexole tablet uses specific acid-base excipient ratios to dissolve rapidly in water.

Targeting IL-11 signaling addresses root causes of obesity and NASH.

Specific antibodies and endopeptidases clear host stem cells, reducing organ toxicity while improving donor engraftment efficiency.

Specific structural modifications in the novel JAK inhibitor achieve high selectivity for JAK1 over JAK3, reducing adverse immune effects.

Allosteric binding avoids orthosteric competition to treat neurological disorders without off-target effects.

Okra polysaccharides bind dietary fats in the stomach to reduce caloric absorption, avoiding gastrointestinal side effects of synthetic lipase inhibitors.

Montbretin A maintains over 80% inhibitory activity during cooking to control postprandial glycemia without complex delivery systems.

Segmenting rosuvastatin and ezetimibe into separate tablet layers prevents oxidative degradation and solubility issues while maintaining stability.

Cationic liposomes deliver genetic material and drugs to glucocorticoid receptor-expressing cancer cells, reducing toxicity to healthy tissues.

Pyridopyrimidine compounds block SK3 ion channels to prevent bone metastasis development.

Carbamate benzoxazine derivatives modulate RORgammaT activity, reducing side effects in inflammatory disease treatment.

Pre-resolving diastereomeric mixtures via preliminary action eliminates unwanted isomers, improving stereochemical purity and yield.

DGAT2 inhibitors resolve inadequate lipid metabolism management by reducing hepatic lipid accumulation and improving insulin sensitivity.

Compound 7Ai inhibits OTUD7A to destabilize EWS-FLI1, addressing limited therapeutic options for Ewing sarcoma.

Novel aminothiazole compounds inhibit cyclin dependent kinases to reactivate silenced tumor-suppressor genes.

Arylcyclopropylacetamide derivatives activate glucokinase to lower blood glucose while limiting brain penetration.

Pyridine-sulfonamide derivatives achieve sigma-2 receptor selectivity over sigma-1 using local quality and parameter changes.

Enamine activation of enones enables catalytic hetero-Diels-Alder reactions with isatins, expanding spirooxindole motif diversity.

Asymmetric press-coated tablet uses thicker equatorial coating to extend lag time without increasing overall tablet size, resolving swallowability trade-offs.

Modified thiazolidinedione structures lower PPARγ activation, reducing sodium reabsorption side effects while maintaining glucose-lowering efficacy.

Optimized purine core structures improve metabolic stability and blood-brain barrier penetration for treating anxiety and depression.

Charge-reversible polymers overcome plasma clearance by switching from anionic to cationic states at low pH, enhancing tumor accumulation.

Type 2 Raf kinase inhibitors bind in DFG-out mode to minimize paradoxical MAPK pathway activation in wild-type B-Raf and KRas mutant tumors.

Enzymatic conversion achieves selective 3-O-sulfation of glucosamine residues, avoiding non-selective side reactions on glucuronic acid.

Topical cellular extracts induce stem cell de-differentiation to reverse scarring and restore aged skin through preliminary action principles.